Other reports soon followed with either CD19-CAR T or CD22-CAR T, expanding our knowledge about this innovative treatment method.70–73 Two very recent publications reported the final results of prospective trials using CAR T cells obtained through different methodology on 30 and 21 patients with relapsed ALL, respectively, including a few adult subjects.74,75 In the first study autologous CD19-CAR T cells induced a CR in 27 (90%) patients (of whom 2 had previously failed blinatumomab, and 15 had relapsed following allogeneic SCT). Here, CD22 is linked to acute lymphoblastic leukemia.